TN2009000287A1 - Cyclized derivatives as eg-5inhibitors - Google Patents

Cyclized derivatives as eg-5inhibitors

Info

Publication number: TN2009000287A1
Authority: TN; Tunisia
Prior art keywords: compounds; pharmaceutically acceptable; cyclized derivatives; cyclized; derivatives
Prior art date: 2007-01-05

Application number

TNP2009000287A

Other languages

English (en)

Inventor

Rustum Boyce

Eric Martin

Weibo Wang

Hong Yang

Paul A Barsanti

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-01-05

Filing date

2009-07-03

Publication date

2010-12-31

2009-07-03 Application filed by Novartis Ag filed Critical Novartis Ag

2010-12-31 Publication of TN2009000287A1 publication Critical patent/TN2009000287A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

TNP2009000287A 2007-01-05 2009-07-03 Cyclized derivatives as eg-5inhibitors TN2009000287A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US88374007P	2007-01-05	2007-01-05
PCT/US2008/050149 WO2008086122A2 (fr)	2007-01-05	2008-01-03	Dérivés cyclisés en tant qu'inhibiteurs d'eg-5

Publications (1)

Publication Number	Publication Date
TN2009000287A1 true TN2009000287A1 (en)	2010-12-31

Family

ID=39577804

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000287A TN2009000287A1 (en)	2007-01-05	2009-07-03	Cyclized derivatives as eg-5inhibitors

Country Status (30)

Country	Link
US (3)	US7820646B2 (fr)
EP (1)	EP2106399A2 (fr)
JP (1)	JP2010515687A (fr)
KR (1)	KR20090097210A (fr)
CN (1)	CN101622247A (fr)
AR (1)	AR064760A1 (fr)
AU (1)	AU2008205169B2 (fr)
BR (1)	BRPI0806264A2 (fr)
CA (1)	CA2674318A1 (fr)
CL (1)	CL2008000029A1 (fr)
CO (1)	CO6561828A2 (fr)
CR (1)	CR10879A (fr)
DO (1)	DOP2009000169A (fr)
EA (1)	EA200900924A1 (fr)
EC (1)	ECSP099485A (fr)
GE (1)	GEP20125415B (fr)
GT (1)	GT200900192A (fr)
HN (1)	HN2009001262A (fr)
MA (1)	MA31080B1 (fr)
MX (1)	MX2009007260A (fr)
NI (1)	NI200900134A (fr)
NZ (1)	NZ577727A (fr)
PE (1)	PE20081850A1 (fr)
SM (1)	SMP200900065B (fr)
SV (1)	SV2009003325A (fr)
TN (1)	TN2009000287A1 (fr)
TW (1)	TW200836722A (fr)
UA (1)	UA97821C2 (fr)
WO (1)	WO2008086122A2 (fr)
ZA (1)	ZA200904175B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8252832B2 (en)	2007-12-14	2012-08-28	Novartis Ag	Kinesin inhibitors as cancer therapeutics
MX2012011910A (es)	2010-04-15	2012-11-29	Novartis Ag	Compuestos de triazol como inhibidores de ksp.
WO2011128388A2 (fr) *	2010-04-15	2011-10-20	Novartis Ag	Composés d'oxazole et de thiazole comme inhibiteurs de ksp
EP2390247A1 (fr) *	2010-05-26	2011-11-30	Netherlands Organisation for Scientific Research (Advanced Chemical Technologies for Sustainability)	Préparation de caprolactone, caprolactam, 2,5-tétrahydrofuranne diméthanol, 1,6-héxanediol ou 1,2,6-hexanetriol à partir de 5-hydroxymethyl-2-furfuraldehyde
GB201113538D0 (en)	2011-08-04	2011-09-21	Karobio Ab	Novel estrogen receptor ligands
US9498540B2 (en)	2013-03-15	2016-11-22	Novartis Ag	Cell proliferation inhibitors and conjugates thereof
CN105451773A (zh) *	2013-03-15	2016-03-30	诺华股份有限公司	细胞增殖抑制剂及其缀合物
KR102329024B1 (ko) *	2013-12-23	2021-11-19	바이엘 파마 악티엔게젤샤프트	키네신 스핀들 단백질(ksp)과의 항체 약물 접합체 (adcs)
JP6971858B2 (ja) *	2015-06-22	2021-11-24	バイエルファーマアクチエンゲゼルシャフト	酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ）
CN105330657B (zh) *	2015-12-08	2019-05-21	华润双鹤药业股份有限公司	5-氯-2-[5-(r)-甲基-1,4-二氮杂环庚烷-1-]苯并恶唑的制备方法
CN105367506B (zh) *	2015-12-08	2021-02-05	华润双鹤药业股份有限公司	手性高哌嗪环的制备方法
EP3919518A1 (fr)	2016-06-15	2021-12-08	Bayer Pharma Aktiengesellschaft	Conjugués anticorps-médicament spécifiques (adc) avec inhibiteurs de ksp et des anticorps anti-cd123
CN110072556B (zh)	2016-12-21	2023-05-02	拜耳制药股份公司	具有ksp抑制剂的特异性抗体药物缀合物(adc)
IL291308B2 (en)	2016-12-21	2024-07-01	Bayer Pharma AG	Antibody drug conjugates (adcs) having enzymatically cleavable groups
EP3806908A1 (fr)	2018-06-18	2021-04-21	Bayer Aktiengesellschaft	Conjugués liant-principe actif inhibant cxcr5 comprenant des éléments de liaison pouvant être fragmentés de manière enzymatique et présentant un profil d'action amélioré
CN119859151A (zh) *	2023-10-19	2025-04-22	北京振东光明药物研究院有限公司	从白土苓中分离得到的生物碱类化合物及其制备方法和应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2550959C3 (de)	1975-11-13	1980-12-04	Hoechst Ag, 6000 Frankfurt	Tetrazolyl-imidazole und Tetrazolyl--benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en)	1983-01-06	1985-02-26	Technology Unlimited, Inc.	Masking of liposomes from RES recognition
GB2157285B (en)	1984-04-11	1987-10-28	Erba Farmitalia	1h, 7h-pyrazolo1, 5-a pyrimidine-7-one derivatives and process for their preparation
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
US4837028A (en)	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5011472A (en)	1988-09-06	1991-04-30	Brown University Research Foundation	Implantable delivery system for biological factors
US5859012A (en) *	1996-04-03	1999-01-12	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
WO1998027108A2 (fr)	1996-12-16	1998-06-25	Fujisawa Pharmaceutical Co., Ltd.	Nouveaux composes amide
US6117940A (en)	1997-10-17	2000-09-12	Mjalli; Adnan M. M.	Amino-ketone solid support templates
US6172087B1 (en)	1998-06-03	2001-01-09	Gpi Nil Holding, Inc.	N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
CA2369549A1 (fr)	1999-04-02	2000-10-12	Robert W. Desimone	Derives d'aminoalkyle-imidazole condenses aryles et heteroaryles et leur utilisation comme antidiabetiques
US6271241B1 (en)	1999-04-02	2001-08-07	Neurogen Corporation	Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US7291641B2 (en)	1999-10-11	2007-11-06	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)	Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US20040132788A1 (en)	1999-10-11	2004-07-08	Chabrier De Lassauniere Pierre-Etienne	Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
TWI292316B (en)	1999-10-11	2008-01-11	Sod Conseils Rech Applic	Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof
US6545004B1 (en)	1999-10-27	2003-04-08	Cytokinetics, Inc.	Methods and compositions utilizing quinazolinones
DE60028227T2 (de)	1999-10-27	2007-03-29	Cytokinetics, Inc., South San Francisco	Chinazolinone benutzende verfahren und zusammenstellungen
AU2001227812A1 (en)	2000-05-02	2001-11-12	Advanced Syntech, Llc A Kentucky Limited Liability Corporation	A novel solid support template for preparation of highly functionalized heterocycle compounds
US6951948B2 (en)	2000-06-05	2005-10-04	Ortho-Mcneil Pharmaceutical, Inc.	Method for synthesis of substituted azole libraries
US6683191B2 (en)	2000-06-05	2004-01-27	Ortho-Mcneil Pharmaceuticals, Inc.	Method for synthesis of substituted azole libraries
NZ523774A (en)	2000-08-01	2004-09-24	Sod Conseils Rech Applic	Imidazolyl derivatives
WO2002028839A1 (fr)	2000-10-06	2002-04-11	Neurogen Corporation	Derives de benzimidazole et d'indole en tant que modulateurs des recepteurs de la corticoliberine
WO2002046168A1 (fr)	2000-12-07	2002-06-13	Astrazeneca Ab	Composes therapeutiques de benzimidazole
EA007538B1 (ru)	2000-12-11	2006-10-27	Туларик Инк.	Антагонисты cxcr3
EP1360180A1 (fr)	2001-01-19	2003-11-12	Cytokinetics, Inc.	Inhibiteurs de la kinesine a base de phenothiazine
US20040132830A1 (en)	2001-01-19	2004-07-08	Finer Jeffrey T	Triphenylmethane kinesin inhibitors
WO2003039460A2 (fr)	2001-11-07	2003-05-15	Merck & Co., Inc.	Inhibiteurs de la kinesine mitotique
WO2003043995A1 (fr)	2001-11-20	2003-05-30	Cytokinetics, Inc.	Procede de racemisation de quinazolinones chirales
ES2291543T3 (es)	2001-12-06	2008-03-01	MERCK & CO., INC.	Inhibicion de kinesina mitotica.
DE60232994D1 (de)	2001-12-06	2009-08-27	Merck & Co Inc	Inhibitoren von mitotischem kinesin
AU2002351183B2 (en)	2001-12-06	2008-05-08	Merck Sharp & Dohme Corp.	Mitotic kinesin inhibitors
WO2003049678A2 (fr)	2001-12-06	2003-06-19	Merck & Co., Inc.	Inhibiteurs mitotiques de la kinesine
US7244723B2 (en)	2001-12-06	2007-07-17	Merck & Co., Inc.	Substituted furopyrimidinones as a mitotic kinesin inhibitors
CA2472470A1 (fr)	2002-01-10	2003-07-24	Neurogen Corporation	Ligands recepteurs de l'hormone de concentration de la melanine: analogues de benzoimidazole substitue
CA2475879A1 (fr)	2002-02-15	2003-08-28	Cytokinetics, Inc.	Synthesis de quinazolinones
ATE448207T1 (de)	2002-03-08	2009-11-15	Merck & Co Inc	Mitotische kinesin-hemmer
DE10211770A1 (de)	2002-03-14	2003-10-02	Boehringer Ingelheim Pharma	Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7026312B2 (en)	2002-03-14	2006-04-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
CN100381437C (zh)	2002-04-17	2008-04-16	赛特凯恩蒂克公司	化合物、组合物和方法
GB0209995D0 (en)	2002-05-01	2002-06-12	Merck Sharp & Dohme	Therapeutic agents
CA2485093A1 (fr)	2002-05-02	2003-11-13	Neurogen Corporation	Derives d'imidazole substitues: ligands du recepteur gaba<sb>a</sb>
WO2004041809A2 (fr)	2002-05-08	2004-05-21	Neurogen Corporation	Imidazolylmethyl pyridine substituee et derives de pyrazine: les ligands des recepteurs gabaa
US7214800B2 (en)	2002-05-09	2007-05-08	Cytokinetics, Inc.	Compounds, compositions, and methods
KR20050036911A (ko)	2002-05-09	2005-04-20	싸이토키네틱스, 인코포레이티드	화합물들, 방법 및 조성물
EP1507534A4 (fr)	2002-05-10	2006-11-08	Cytokinetics Inc	Composes, compositions et procedes
WO2003097643A1 (fr)	2002-05-17	2003-11-27	Neurogen Corporation	Derives d'imidazole a cycles fusionnes se fixant aux recepteurs gabaa, ligands des recepteurs gabaa
CA2483627A1 (fr) *	2002-05-23	2003-12-04	Merck & Co., Inc.	Inhibiteurs de kinesine mitotique
JP2005536475A (ja)	2002-05-23	2005-12-02	サイトキネティクス・インコーポレーテッド	化合物、組成物、および方法
CA2489367A1 (fr)	2002-06-14	2003-12-24	Cytokinetics, Inc.	Composes, compositions et procedes
DE60329756D1 (de)	2002-06-14	2009-12-03	Merck & Co Inc	Mitotische kinesin-hemmer
CA2486215A1 (fr)	2002-06-14	2003-12-24	Merck & Co., Inc.	Inhibiteurs de kinesine mitotique
US20060134767A1 (en)	2002-07-08	2006-06-22	Buser-Doepner Carolyn A	Mitotic kinesin binding site
EP1539727B1 (fr)	2002-07-17	2009-02-18	Cytokinetics, Inc.	Composes, compositions et methodes pour le traitement des maladies proliferatives cellulaires
WO2004009036A2 (fr)	2002-07-23	2004-01-29	Cytokinetics, Inc.	Composes, compositions et procedes
US20040048853A1 (en)	2002-08-21	2004-03-11	Gustave Bergnes	Compounds, compositions, and methods
JP2005539062A (ja)	2002-09-13	2005-12-22	サイトキネティクス・インコーポレーテッド	化合物、組成物および方法
CN100579579C (zh)	2002-10-01	2010-01-13	诺华疫苗和诊断公司	抗癌及抗感染性疾病组合物及其使用方法
ATE335732T1 (de)	2002-11-08	2006-09-15	Neurogen Corp	4-imidazol-1-ylmethylpyrimidinderivate als liganden für gabaa-rezeptoren
WO2004055008A1 (fr) *	2002-12-13	2004-07-01	Smithkline Beecham Corporation	Composes, compositions et methodes
JP2006515886A (ja)	2003-01-17	2006-06-08	サイトキネティクス・インコーポレーテッド	化合物、組成物、および方法
WO2004071448A2 (fr)	2003-02-12	2004-08-26	Transtech Pharma Inc.	Derives d'azole substitues comme agents therapeutiques
JP2007500213A (ja)	2003-05-07	2007-01-11	サイトキネティクス・インコーポレーテッド	化合物、組成物および方法
JP2007500746A (ja)	2003-05-15	2007-01-18	サイトキネティクス・インコーポレーテッド	化合物、組成物および方法
CA2528771A1 (fr)	2003-06-20	2004-12-29	Chiron Corporation	Composes de pyridino[1,2-a]pyrimidin-4-one servant d'agents anticancereux
EP1682534A2 (fr) *	2003-11-03	2006-07-26	Cytokinetics, Inc.	Derives de pyrimidin-4-one, compositions et methodes
NZ548208A (en)	2004-02-12	2010-09-30	Transtech Pharma Inc	Substituted azole derivatives, compositions, and methods of use
AU2005233576A1 (en)	2004-04-06	2005-10-27	Novartis Vaccines And Diagnostics, Inc.	Mitotic kinesin inhibitors
US20080132549A1 (en)	2004-04-14	2008-06-05	Pfizer Inc.	Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids
US7618981B2 (en)	2004-05-06	2009-11-17	Cytokinetics, Inc.	Imidazopyridinyl-benzamide anti-cancer agents
ES2311992T3 (es)	2004-05-21	2009-02-16	Novartis Vaccines And Diagnostics, Inc.	Derivados de quinolina sustituida com,o inhibidores de cinesina mitotica.
TW200612958A (en) *	2004-06-18	2006-05-01	Chiron Corp	Substituted imidazole derivatives
CA2584979A1 (fr)	2004-10-19	2006-05-11	Novartis Vaccines And Diagnostics, Inc.	Derives d'indole et de benzimidazole
MY147188A (en)	2005-08-09	2012-11-14	Novartis Ag	Substituted imidazole compounds as ksp inhibitors
KR20090081020A (ko)	2006-11-13	2009-07-27	노파르티스 아게	Ｋｓｐ 억제제로서의 치환된 피라졸 및 트리아졸 화합물

2008
- 2008-01-03 KR KR1020097016289A patent/KR20090097210A/ko not_active Withdrawn
- 2008-01-03 CN CN200880007148A patent/CN101622247A/zh active Pending
- 2008-01-03 CA CA002674318A patent/CA2674318A1/fr not_active Abandoned
- 2008-01-03 JP JP2009544977A patent/JP2010515687A/ja active Pending
- 2008-01-03 EP EP08705667A patent/EP2106399A2/fr not_active Withdrawn
- 2008-01-03 GE GEAP200811346A patent/GEP20125415B/en unknown
- 2008-01-03 WO PCT/US2008/050149 patent/WO2008086122A2/fr not_active Ceased
- 2008-01-03 AU AU2008205169A patent/AU2008205169B2/en not_active Ceased
- 2008-01-03 US US11/969,164 patent/US7820646B2/en not_active Expired - Fee Related
- 2008-01-03 NZ NZ577727A patent/NZ577727A/en not_active IP Right Cessation
- 2008-01-03 BR BRPI0806264-1A patent/BRPI0806264A2/pt not_active IP Right Cessation
- 2008-01-03 EA EA200900924A patent/EA200900924A1/ru unknown
- 2008-01-03 MX MX2009007260A patent/MX2009007260A/es not_active Application Discontinuation
- 2008-01-04 AR ARP080100042A patent/AR064760A1/es not_active Application Discontinuation
- 2008-01-04 TW TW097100432A patent/TW200836722A/zh unknown
- 2008-01-04 PE PE2008000091A patent/PE20081850A1/es not_active Application Discontinuation
- 2008-01-04 CL CL200800029A patent/CL2008000029A1/es unknown
- 2008-03-01 UA UAA200906929A patent/UA97821C2/ru unknown
2009
- 2009-06-15 ZA ZA200904175A patent/ZA200904175B/xx unknown
- 2009-06-19 CR CR10879A patent/CR10879A/es unknown
- 2009-06-30 MA MA32061A patent/MA31080B1/fr unknown
- 2009-07-02 CO CO09068496A patent/CO6561828A2/es not_active Application Discontinuation
- 2009-07-02 DO DO2009000169A patent/DOP2009000169A/es unknown
- 2009-07-02 NI NI200900134A patent/NI200900134A/es unknown
- 2009-07-03 EC EC2009009485A patent/ECSP099485A/es unknown
- 2009-07-03 SV SV2009003325A patent/SV2009003325A/es not_active Application Discontinuation
- 2009-07-03 GT GT200900192A patent/GT200900192A/es unknown
- 2009-07-03 HN HN2009001262A patent/HN2009001262A/es unknown
- 2009-07-03 TN TNP2009000287A patent/TN2009000287A1/fr unknown
- 2009-07-23 SM SM200900065T patent/SMP200900065B/it unknown
2010
- 2010-09-15 US US12/882,473 patent/US20110003791A1/en not_active Abandoned
2012
- 2012-04-03 US US13/438,569 patent/US20120189623A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HN2009001262A (es)	2012-01-09
JP2010515687A (ja)	2010-05-13
EP2106399A2 (fr)	2009-10-07
US20120189623A1 (en)	2012-07-26
CA2674318A1 (fr)	2008-07-17
WO2008086122A2 (fr)	2008-07-17
KR20090097210A (ko)	2009-09-15
CR10879A (es)	2009-08-05
DOP2009000169A (es)	2009-08-31
ZA200904175B (en)	2010-04-28
PE20081850A1 (es)	2009-02-05
CO6561828A2 (es)	2012-11-15
AU2008205169B2 (en)	2012-02-02
GT200900192A (es)	2010-06-24
US20080207589A1 (en)	2008-08-28
TW200836722A (en)	2008-09-16
MX2009007260A (es)	2009-07-10
MA31080B1 (fr)	2010-01-04
SMAP200900065A (it)	2009-09-07
SMP200900065B (it)	2010-09-10
ECSP099485A (es)	2009-08-28
CN101622247A (zh)	2010-01-06
AU2008205169A1 (en)	2008-07-17
EA200900924A1 (ru)	2009-12-30
WO2008086122A3 (fr)	2008-10-16
US20110003791A1 (en)	2011-01-06
AR064760A1 (es)	2009-04-22
SV2009003325A (es)	2011-08-09
US7820646B2 (en)	2010-10-26
NI200900134A (es)	2010-07-05
GEP20125415B (en)	2012-03-12
UA97821C2 (en)	2012-03-26
CL2008000029A1 (es)	2008-04-04
NZ577727A (en)	2012-03-30
BRPI0806264A2 (pt)	2011-08-30

Publication	Publication Date	Title
TN2009000287A1 (en)	2010-12-31	Cyclized derivatives as eg-5inhibitors
TW200612958A (en)	2006-05-01	Substituted imidazole derivatives
MX2007004699A (es)	2007-06-14	Derivados de indol y bencimidazol.
TW200801000A (en)	2008-01-01	Spiroindolinone derivatives
MX2012009186A (es)	2012-08-23	Pirrolidina-2-carboxamidas sustituidas.
MX2011013771A (es)	2012-02-22	Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17.
MX2010003155A (es)	2010-04-01	Derivados de ciclopropil aril amida y uso de los mismos.
TW200833675A (en)	2008-08-16	Nicotinamide derivatives
GEP201606555B (en)	2016-10-10	Compounds and compositions for modulating egfr activity
MX2010003156A (es)	2010-04-01	Derivados de aril amida substituida con tetrazol y usos de los mismos.
WO2008108378A3 (fr)	2008-12-04	Dérivé bicyclique d'oxomorpholine
MX2011008176A (es)	2011-08-17	Derivados de 3,3'-espiroindolinona como agentes anticancerigenos.
UA105229C2 (uk)	2014-04-25	Фармацевтичний склад
UA94606C2 (ru)	2011-05-25	Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
TW200728307A (en)	2007-08-01	Novel spirochromanone derivatives
TN2009000178A1 (en)	2010-10-18	Substituted pyrazole and triazole compounds as ksp inhibitors
SI1753723T1 (sl)	2009-04-30	Substituirani kinolinski derivati kot mitotiäśni kinesinski inhibitorji
MX2012003982A (es)	2012-05-08	Pirrolidinas n-substituidas.
MX2009007713A (es)	2009-07-29	Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
MY147188A (en)	2012-11-14	Substituted imidazole compounds as ksp inhibitors
MX2009008028A (es)	2009-08-07	Agentes antiparasitarios.
TN2012000105A1 (en)	2013-09-19	Spirolactam derivatives and uses of same
IL195016A0 (en)	2009-08-03	1h-indol-5-yl-piperazin-1-yl-methanone derivatives
MY161749A (en)	2017-05-15	Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
WO2007017728A3 (fr)	2008-04-03	Nouveaux composes heterocycliques